ILMN
Illumina, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$218.74
−1.32%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.5B | 4.3B | 4.4B | 4.5B | 4.6B |
| Cost of Revenue | 1.5B | 1.4B | 1.5B | 1.8B | 1.6B |
| Gross Profit | 3.0B | 2.9B | 2.9B | 2.7B | 3.0B |
| Operating Expenses | |||||
| R&D Expense | 958.0M | 951.0M | 1.2B | 1.4B | 1.3B |
| SG&A Expense | 1.1B | 1.1B | 1.1B | 1.6B | 1.3B |
| General & Admin Expense | 273.0M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 1.4B | 847.0M | 4.5B |
| Total Operating Expenses | 2.1B | 2.0B | 3.7B | 3.8B | 7.2B |
| Cost and Expenses | 3.6B | 3.5B | 5.2B | 5.6B | 8.8B |
| Operating Income (EBIT) | 942.0M | 864.0M | (833.0M) | (1.1B) | (4.2B) |
| Non-Operating | |||||
| Interest Income | 30.0M | 40.0M | 46.0M | 58.0M | 11.0M |
| Interest Expense | 75.0M | 101.0M | 100.0M | 77.0M | 26.0M |
| Net Interest Income | (45.0M) | (61.0M) | (54.0M) | (19.0M) | (15.0M) |
| Other Non-Op Income/Expense | 73.0M | 222.0M | (346.0M) | (48.0M) | (157.0M) |
| Non-Operating Income (excl Interest) | (148.0M) | (323.0M) | 246.0M | (29.0M) | 131.0M |
| EBT (Pre-Tax Income) | 1.0B | 1.1B | (1.2B) | (1.1B) | (4.3B) |
| Income Tax Expense | 190.0M | 236.0M | 44.0M | 44.0M | 68.0M |
| Bottom Line | |||||
| Net Income | 825.0M | 850.0M | (1.2B) | (1.2B) | (4.4B) |
| Earnings from Cont. Ops | 825.0M | 850.0M | (1.2B) | (1.2B) | (4.4B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 825.0M | 850.0M | (1.2B) | (1.2B) | (4.4B) |
| Per Share | |||||
| Basic EPS | $5.41 | $5.48 | ($7.69) | ($7.35) | ($28.05) |
| Diluted EPS | $5.36 | $5.45 | ($7.69) | ($7.35) | ($28.05) |
| Revenue Per Share | $29.75 | $27.99 | $27.50 | $28.51 | $29.20 |
| Shares | |||||
| Basic Shares Outstanding | 151.0M | 155.0M | 159.0M | 158.0M | 157.0M |
| Diluted Shares Outstanding | 153.0M | 156.0M | 159.0M | 158.0M | 157.0M |
| Profitability Metrics | |||||
| EBITDA | 1.4B | 1.5B | (725.0M) | (608.0M) | (3.9B) |
| D&A | 273.0M | 270.0M | 354.0M | 432.0M | 394.0M |
| EBIT | 1.1B | 1.2B | (1.1B) | (1.0B) | (4.3B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026